Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms.
early-onset gastroenteropancreatic neuroendocrine neoplasms
epidemiology
incidence
mortality
survival
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
06
2023
accepted:
14
08
2023
medline:
14
9
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
epublish
Résumé
The epidemiologic trends and survival related to early-onset gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have not been well explored. Trends in the incidence and incidence-based mortality of early-onset GEP-NENs between 1975 and 2018 were obtained from the Surveillance, Epidemiology, and End Results database, and were stratified by age, sex, race, tumor site, stage, and grade. Associated population data were used to determine overall survival (OS) and independent prognostic factors for patients with early-onset GEP-NENs. A total of 17299 patients diagnosed with early-onset GEP-NENs were included in this study. Results revealed an increase in the incidence (5.95% per year, 95% confidence interval (CI), 5.75-6.14%) and incidence-based mortality (4.24% per year, 95% CI, 3.92-4.56%) for early-onset GEP-NENs from 1975 to 2018, with higher rates of increase than those of later-onset GEP-NENs (incidence: 4.45% per year, 95% CI, 4.38-4.53; incidence-based mortality: 4.13% per year, 95% CI, 3.89-4.37; respectively). Increases in incidence were observed across all age, races, tumor sites, grades, and stages, except for patients with unknown stage. Compared to those with later-onset GEP-NENs, a higher proportion of female gender (54.5% vs. 49.0%, The incidence and incidence-based mortality rates of early-onset GEP-NENs have steadily increased over time, with higher rates of increase than those of later-onset GEP-NENs. The clinical characteristics and survival were different between early-onset and later-onset GEP-NENs groups. Race, marital status, stage, grade, chemotherapy, and primary site were independent prognostic factors for early-onset GEP-NENs. Further investigations are warranted to better understand the characteristics of this disease subgroup.
Sections du résumé
Background
The epidemiologic trends and survival related to early-onset gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have not been well explored.
Methods
Trends in the incidence and incidence-based mortality of early-onset GEP-NENs between 1975 and 2018 were obtained from the Surveillance, Epidemiology, and End Results database, and were stratified by age, sex, race, tumor site, stage, and grade. Associated population data were used to determine overall survival (OS) and independent prognostic factors for patients with early-onset GEP-NENs.
Results
A total of 17299 patients diagnosed with early-onset GEP-NENs were included in this study. Results revealed an increase in the incidence (5.95% per year, 95% confidence interval (CI), 5.75-6.14%) and incidence-based mortality (4.24% per year, 95% CI, 3.92-4.56%) for early-onset GEP-NENs from 1975 to 2018, with higher rates of increase than those of later-onset GEP-NENs (incidence: 4.45% per year, 95% CI, 4.38-4.53; incidence-based mortality: 4.13% per year, 95% CI, 3.89-4.37; respectively). Increases in incidence were observed across all age, races, tumor sites, grades, and stages, except for patients with unknown stage. Compared to those with later-onset GEP-NENs, a higher proportion of female gender (54.5% vs. 49.0%,
Conclusions
The incidence and incidence-based mortality rates of early-onset GEP-NENs have steadily increased over time, with higher rates of increase than those of later-onset GEP-NENs. The clinical characteristics and survival were different between early-onset and later-onset GEP-NENs groups. Race, marital status, stage, grade, chemotherapy, and primary site were independent prognostic factors for early-onset GEP-NENs. Further investigations are warranted to better understand the characteristics of this disease subgroup.
Identifiants
pubmed: 37701903
doi: 10.3389/fendo.2023.1241724
pmc: PMC10493410
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1241724Informations de copyright
Copyright © 2023 Yao, Hu, Jiang, Fan, Yuan, Shi and Lin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Prostate. 2021 Feb;81(2):118-126
pubmed: 33152137
Semin Cancer Biol. 2022 Feb;79:141-162
pubmed: 33905872
Endocr Relat Cancer. 2016 Feb;23(2):93-100
pubmed: 26604321
JAMA Intern Med. 2023 Mar 1;183(3):183-190
pubmed: 36648785
JAMA Netw Open. 2021 Sep 1;4(9):e2124750
pubmed: 34554237
Clin Transl Gastroenterol. 2019 Jul;10(7):e00059
pubmed: 31259751
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Clin Gastroenterol Hepatol. 2019 Oct;17(11):2212-2217.e1
pubmed: 30580091
J Clin Oncol. 2018 Jul 20;36(21):2169-2180
pubmed: 29874135
Oxid Med Cell Longev. 2021 Jun 26;2021:9985814
pubmed: 34257826
Crit Rev Oncol Hematol. 2022 Jan;169:103572
pubmed: 34954047
Int J Cancer. 2018 Oct 15;143(8):1876-1883
pubmed: 29744856
Cancer Discov. 2023 Mar 1;13(3):538-551
pubmed: 36757194
J Clin Oncol. 2016 May 10;34(14):1626-33
pubmed: 26951318
Gastroenterology. 2020 Dec;159(6):2238-2240.e4
pubmed: 32777286
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Metabolites. 2022 Nov 02;12(11):
pubmed: 36355141
Lancet Oncol. 2022 Jan;23(1):27-52
pubmed: 34871551
Int J Cancer. 2008 Aug 15;123(4):867-73
pubmed: 18491401
Endocr Relat Cancer. 2023 May 11;30(6):
pubmed: 36947458
N Engl J Med. 2017 Apr 13;376(15):1419-1429
pubmed: 28402773
Cancer Causes Control. 2013 Sep;24(9):1737-46
pubmed: 23812550
Ann Pathol. 2020 Apr;40(2):120-133
pubmed: 32035641
Nat Rev Clin Oncol. 2022 Oct;19(10):656-673
pubmed: 36068272
J Endocrinol Invest. 2023 Feb;46(2):213-234
pubmed: 36038743
Lancet. 2022 Jul 16;400(10347):185-235
pubmed: 35843246
Endocr Relat Cancer. 2014 May 06;21(3):R153-63
pubmed: 24322304
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):959-65
pubmed: 18398037
Neuroendocrinology. 2015;101(2):133-42
pubmed: 25613442
Endocrinol Diabetes Nutr (Engl Ed). 2023 Mar;70 Suppl 1:63-73
pubmed: 36396595
Endoscopy. 2013;45(1):51-9
pubmed: 23212726
Lancet Public Health. 2019 Mar;4(3):e137-e147
pubmed: 30733056
J Clin Oncol. 2022 Aug 20;40(24):2662-2680
pubmed: 35839438
Cancer. 2001 Oct 15;92(8):2204-10
pubmed: 11596039
Diabetologia. 2013 Jul;56(7):1471-88
pubmed: 23677041
Cancer. 2016 Jan 1;122(1):116-23
pubmed: 26441212
Ann Oncol. 2016 Jan;27(1):68-81
pubmed: 26487581
Lancet. 2021 Jun 19;397(10292):2337-2360
pubmed: 34051883
Cancer Med. 2023 Mar;12(6):7327-7338
pubmed: 36621839